Home › ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...
 

Keywords :   


ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...

2014-06-01 18:26:53| Logistics - Topix.net

ImmunoGen, Inc. , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced the presentation of favorable clinical findings with SAR3419 from the STARLYTE Phase II trial in diffuse large B-cell lymphoma .

Tags: data phase clinical favorable

Category:Transportation and Logistics

Latest from this category

All news
»
13.05HigherDoses New Red Light Hat Gives Hair Growth the Green Light
13.05Naturium Launches Glow Getter Body Oil Ahead of Summer 2024
13.05Aptoide sells stake in Faurecia Aptoide Automotive
13.05AppleTV+ fastest growing major SVOD service in Q1'24
13.05SafeShark finds connected devices not compliant with UK security law
13.05Zattoo deploys Bitmovin Player
13.05Altice USA residential video RGUs down 77,700 in 1Q 2024
13.05Fubo unveils new CTV ad offerings at 2024 IAB NewFronts
More »